Premium
Malignant melanoma as second malignant neoplasm in long‐term childhood cancer survivors: A systematic review
Author(s) -
Braam Katja. I.,
Overbeek Annelies,
Kaspers Gertjan J.L.,
Ronckers Cecile M.,
Schoutenvan Meeteren Annette Y.N.,
Van DulmenDen Broeder Eline,
Veening Margreet A.
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24023
Subject(s) - medicine , melanoma , retinoblastoma , cancer , oncology , sarcoma , radiation therapy , population , neoplasm , childhood cancer , dermatology , pathology , cancer research , biochemistry , chemistry , environmental health , gene
This systematic review provides information on malignant melanoma as second malignant neoplasm (SMN) after childhood cancer and evaluates its risk factors. Study reports describing incidences of SMN and malignant melanoma as SMN in a population of childhood cancer survivors (CCS) were included. Of 151,575 CCS, 4,010 (2.6%) children developed an SMN, 212 of which were melanoma (5.3% or 0.14% of all CCS). The following risk factors for malignant melanoma as SMN were identified: radiotherapy, or the combination alkylating agents and anti‐mitotic drugs. Melanomas are most frequently observed after Hodgkin disease, hereditary retinoblastoma, soft tissue sarcoma, and gonadal tumors. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc.